

Resource Summary Report

Generated by [NIF](#) on Sep 7, 2026

NCI-H1650

RRID:CVCL_1483

Type: Cell Line

Proper Citation

RRID:CVCL_1483

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1483

Proper Citation: RRID:CVCL_1483

Description: Cell line NCI-H1650 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Minimally invasive lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:8806092](#), [PMID:11030152](#), [PMID:17332333](#), [PMID:18083107](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22433462](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28766886](#), [PMID:29681454](#), [PMID:30710758](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:32586373](#), [PMID:35117401](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H1650

Synonyms: H1650, H-1650, H1650_CO, NCIH1650

Cross References: BTO:BTO_0005243, CLO:CLO_0008007, EFO:EFO_0002260, CLDB:cl7182, AddexBio:C0016015/4961, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-

MTAB-3610, ATCC:CRL-5883, BioGRID_ORCS_Cell_line:540, BioSample:SAMN03472182, BioSample:SAMN10987889, cancercellines:CVCL_1483, CCRID:1101HUM-PUMC000251, CCRID:3101HUMSCSP592, CCRID:3101HUMTCHu152, Cell_Model_Passport:SIDM00745, ChEMBL-Cells:ChEMBL3308800, ChEMBL-Targets:ChEMBL1075518, CLS:305059, Cosmic:687800, Cosmic:877429, Cosmic:903598, Cosmic:1017829, Cosmic:1028942, Cosmic:1047096, Cosmic:1128242, Cosmic:1146883, Cosmic:1212188, Cosmic:1239904, Cosmic:1571738, Cosmic:1600606, Cosmic:1741779, Cosmic:1795296, Cosmic:1802299, Cosmic:1891894, Cosmic:1995530, Cosmic:2042866, Cosmic:2125236, Cosmic-CLP:687800, DepMap:ACH-000035, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:687800, GEO:GSM108819, GEO:GSM108820, GEO:GSM206474, GEO:GSM253384, GEO:GSM274795, GEO:GSM274828, GEO:GSM434313, GEO:GSM782115, GEO:GSM784207, GEO:GSM794324, GEO:GSM817086, GEO:GSM827475, GEO:GSM844623, GEO:GSM887373, GEO:GSM888451, GEO:GSM1374703, GEO:GSM1670181, GEO:GSM1887942, GEO:GSM1888018, IARC_TP53:21543, ICLC:HTL06002, IGRhCellID:H1650_COGeo, IGRhCellID:NCIH1650, KCLB:91650, LiGeA:CCLE_526, LINCS_LDP:LCL-1612, Lonza:1418, PharmacDB:NCIH1650_1028_2019, PRIDE:PXD011315, PRIDE:PXD030304, Progenetix:CVCL_1483, PubChem_Cell_line:CVCL_1483, Ubigen:YC-C110, Wikidata:Q54907838

ID: CVCL_1483

Record Creation Time: 20220427T220838+0000

Record Last Update: 20260905T181242+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H1650.

No alerts have been found for NCI-H1650.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 419 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Feng X, et al. (2026) FOSL2-induced transcriptional activation of L1CAM promotes progression of lung adenocarcinoma via the PI3K/AKT/mTOR signaling pathway. International immunopharmacology, 168(Pt 1), 115810.

Gao Y, et al. (2026) AMT inhibits the progression of non-small cell lung cancer by suppressing the PI3K/AKT/GSK-3 β /catenin pathway via H3K27me3 regulation.

European journal of pharmacology, 1011, 178460.

Kim D, et al. (2026) Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR-NK Therapeutic Strategies. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(36), e21188.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD⁺ to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.

Lee CH, et al. (2026) Dynamic 3D imaging system detects vasculogenic mimicry and screens inhibitors in EGFR-mutant lung cancer. *Translational research : the journal of laboratory and clinical medicine*, 296, 122.

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. *Cancer research*, 86(5), 1194.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. *Cancer research communications*, 5(1), 24.

Fu X, et al. (2025) A cancer-specific antigen drives histone acetylation by stabilizing the acetyltransferases. *Cell reports*, 44(10), 116408.

Sakai T, et al. (2025) Utility of CK8/18 in identifying circulating tumor cells derived from lesions in patients with non-small cell lung cancer. *Translational lung cancer research*, 14(6), 2100.

Navin I, et al. (2025) TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. *Cancer immunology research*, 13(10), 1576.

Harper NW, et al. (2025) RNA Pol II inhibition activates cell death independently from the loss of transcription. *Cell*.

Jeong J, et al. (2025) NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. *Nature*.

Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. *Cell reports*, 44(6), 115722.

Civita S, et al. (2025) Nanoscale engagement of programmed death ligand 1 (PD-L1) in membrane lipid raft domains of cancer cells. *The FEBS journal*.

Prevost CT, et al. (2025) NRF2 regulates lipid droplet dynamics to prevent lipotoxicity. *iScience*, 28(7), 112925.

Wang C, et al. (2025) KDELR3 is transcriptionally activated by FOXM1 and accelerates lung adenocarcinoma growth and metastasis via inhibiting endoplasmic reticulum stress-induced cell apoptosis. *Human cell*, 38(4), 106.

Chen Y, et al. (2025) Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy. *Cell reports. Medicine*, 6(12), 102513.

Zhang J, et al. (2025) A novel sensitizer reduces EGFR-TKI resistance by regulating the PI3K/Akt/mTOR pathway and autophagy. *Heliyon*, 11(1), e41104.

Li Q, et al. (2025) CircPTK2 enhances non-small cell lung cancer proliferation by inhibiting cellular senescence through stabilizing NFYA and elevating FOXM1. *British journal of pharmacology*.